1. Home
  2. TARS vs NHC Comparison

TARS vs NHC Comparison

Compare TARS & NHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$60.59

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo National HealthCare Corporation

NHC

National HealthCare Corporation

HOLD

Current Price

$193.54

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TARS
NHC
Founded
2016
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Hospital/Nursing Management
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.9B
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
TARS
NHC
Price
$60.59
$193.54
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$89.00
N/A
AVG Volume (30 Days)
466.4K
97.7K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
1.46%
EPS Growth
48.21
17.46
EPS
N/A
2.27
Revenue
$451,360,000.00
$1,517,781,000.00
Revenue This Year
$56.43
N/A
Revenue Next Year
$30.19
N/A
P/E Ratio
N/A
$86.16
Revenue Growth
146.71
16.09
52 Week Low
$38.51
$93.54
52 Week High
$85.25
$205.06

Technical Indicators

Market Signals
Indicator
TARS
NHC
Relative Strength Index (RSI) 46.26 55.60
Support Level $56.90 $154.31
Resistance Level $67.24 $205.06
Average True Range (ATR) 2.61 6.21
MACD 0.37 0.06
Stochastic Oscillator 52.62 64.42

Price Performance

Historical Comparison
TARS
NHC

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About NHC National HealthCare Corporation

National Healthcare Corp provides long-term care facilities. Its principal business includes operating skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services and Home care and hospice services. The majority of revenue is derived from the Inpatient services segment.

Share on Social Networks: